Related Experiment Video
Updated: Mar 11, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.6K
Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?
1Hospital Clínic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Carrer del Rosselló, 08036 Barcelona, Spain.
Hematology/Oncology Clinics of North America
|November 28, 2016
Summary
Limited-stage diffuse large B-cell lymphoma (DLBCL) treatment is evolving. While combined modality therapy was historical, chemotherapy-only strategies are now more frequent due to survival and toxicity concerns, with PET-guided approaches under investigation.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Diffuse large B-cell lymphoma (DLBCL) is diagnosed in limited-stage disease in about 30% of patients.
- Historically, abbreviated chemotherapy combined with involved-field radiotherapy (IFRT) was the standard treatment.
- Concerns regarding long-term survival and delayed toxicity have shifted treatment paradigms.
Purpose of the Study:
- To review current treatment strategies for limited-stage DLBCL.
- To discuss the evolving role of chemotherapy-only approaches and PET-guided therapy.
- To emphasize the importance of individualized treatment and long-term follow-up.
Main Methods:
- Literature review of historical and current treatment modalities for limited-stage DLBCL.
- Analysis of treatment outcomes, focusing on survival and toxicity.
- Discussion of emerging therapeutic strategies, including PET-guided approaches.
Main Results:
- Chemotherapy-only strategies are increasingly favored over combined modality therapy.
- Patient performance, clinical risks, and disease sites are critical factors in treatment selection.
- The risk of late relapse necessitates vigilant long-term patient monitoring.
Conclusions:
- Treatment decisions for limited-stage DLBCL must be individualized based on patient-specific factors.
- PET-guided strategies and incorporation of biological features are crucial for future advancements.
- Long-term follow-up is essential due to the recognized risk of late relapse.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K